Ownership and insider activity for Biohaven Ltd. (BHVN): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that i...
Price
| Price | $15.16 (closing price, November 2, 2026) |
| Market Cap | $2.3B |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-15 | Gentile Kimberly | A-Award | 1,000 | $12K |
| 2026-08-06 | Yetimoglu John | |||
| 2026-07-09 | Volles Warren Karl | |||
| 2026-07-09 | Volles Warren Karl | 300,000 | $2.1M | |
| 2026-07-09 | Volles Warren Karl | 78,750 | $2.3M | |
| 2026-07-09 | Volles Warren Karl | 95,250 | $4.0M | |
| 2026-07-09 | Volles Warren Karl | 83,000 | $3.2M | |
| 2026-07-09 | Volles Warren Karl | 175,000 | $2.0M | |
| 2026-07-09 | Volles Warren Karl | 14,000 | ||
| 2026-04-28 | Mehta Kishan | A-Award | 68,693 | $660K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $131.5M | $264.2M | $316.7M | $82.5M | $76.1M | $204.9M | $248.4M | $99.1M | $230.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $260.5M | $133.4M | $386.9M | $89.2M |
| Receivables | 0 | 0 | 0 | 0 | $9.9M | $46.1M | $13.3M | $2.6M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $136.7M | $272.3M | $328.3M | $89.8M | $94.8M | $587.0M | $442.4M | $538.5M | $368.3M |
| Property, Plant & Equipment | $2.3M | $6.2M | $8.2M | $13.6M | $18.2M | $52.4M | $48.6M | $53.7M | $16.0M |
| Goodwill | 0 | 0 | 0 | 0 | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M |
| Intangible Assets | 0 | 0 | 0 | 0 | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M |
| Total Assets | $146.9M | $290.0M | $344.3M | $111.5M | $142.1M | $661.8M | $513.2M | $615.1M | $451.4M |
| Accounts Payable | $4.7M | $10.8M | $14.1M | $2.8M | $4.8M | $10.7M | $15.6M | $18.0M | $11.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $9.4M | $19.5M | $66.2M | $29.9M | $41.9M | $90.0M | $55.4M | $154.2M | $115.9M |
| Long-term Debt | 0 | $117.5M | 0 | 0 | 0 | 0 | 0 | 0 | $238.9M |
| Total Liabilities | $14.9M | $139.1M | $351.7M | $34.7M | $47.4M | $123.0M | $85.2M | $191.7M | $399.4M |
| Retained Earnings | -$202.6M | -$443.6M | -$972.4M | 0 | 0 | -$91.1M | -$499.3M | -$1.35B | -$2.08B |
| Total Equity | $132.0M | $150.9M | -$7.4M | $16.8M | $34.7M | $538.8M | $428.0M | $423.4M | $52.1M |
| Total Debt | 0 | $117.5M | 0 | $3.6M | $2.8M | $33.6M | $30.9M | $36.6M | $284.6M |
| Net Debt | -$131.5M | -$146.7M | -$316.7M | -$78.9M | -$73.3M | -$431.7M | -$350.9M | -$449.4M | -$34.5M |
| Working Capital | $127.2M | $252.8M | $262.1M | $59.9M | $52.9M | $496.9M | $387.0M | $384.2M | $252.4M |
Financial Health
| Debt / Equity | -3.06 |
| Current Ratio | 3.05 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -9.42 |
Profitability
| Return on Equity | -2,271.87% |
| Return on Invested Capital | -255.03% |
| Return on Assets | -205.81% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: VERA · CLDX · IMNM · PHVS · ABCL
Explore sector: Healthcare · Biotechnology
More sections of BHVN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks